Puri S K, Dutta G P
Division of Microbiology, Central Drug Research Institute, Lucknow, India.
Chemotherapy. 1989;35(3):187-92. doi: 10.1159/000238669.
The antimalarial activity of a new macrolide antibiotic, midecamycin, has been evaluated against a sensitive strain of Plasmodium berghei, a chloroquine-resistant strain of P. yoelii nigeriensis and a simian parasite, P. cynomolgi B. The ED50 and ED90 values of this antibiotic administered in two divided daily doses were found to be 37.15 +/- 3.51 and 100.84 +/- 7.54 mg/kg, respectively, against P. berghei and 362.34 +/- 85.33 and 878.04 +/- 10.02 mg/kg, respectively, against P. yoelii nigeriensis. Doses above 45 mg/kg for 4 days significantly extended the mean survival time of treated mice infected with either of the two parasites. However, no appreciable blood schizontocidal (at 100 mg/kg X 7 days), anti-relapse (at 100 mg/kg X 7 days) or causal prophylactic activities (at 200 mg/kg X 3 days) were observed against P. cynomolgi infection in rhesus monkeys.
一种新型大环内酯类抗生素麦迪霉素对伯氏疟原虫敏感株、约氏疟原虫尼日尔亚种氯喹耐药株以及猴疟原虫食蟹猴疟原虫B的抗疟活性进行了评估。该抗生素每日分两次给药，对伯氏疟原虫的半数有效剂量（ED50）和90%有效剂量（ED90）分别为37.15±3.51毫克/千克和100.84±7.54毫克/千克，对约氏疟原虫尼日尔亚种的ED50和ED90分别为362.34±85.33毫克/千克和878.04±10.02毫克/千克。45毫克/千克以上剂量连续给药4天可显著延长感染上述两种疟原虫之一的治疗小鼠的平均存活时间。然而，对于恒河猴感染食蟹猴疟原虫，未观察到明显的血内裂殖体杀灭作用（100毫克/千克×7天）、抗复发作用（100毫克/千克×7天）或病因性预防作用（200毫克/千克×3天）。
